The Latest Breaking News from FDA

Prime energy drink could be probed by FDA over high caffeine claims

The FDA is being asked to look into Logan Paul and KSI’s energy drink, which has the caffeine of 6 Coke cans

Evening Standard · Jul 9, 2023

Logan Paul’s energy drink with the caffeine of six Coke cans faces calls for FDA probe

An influencer-backed energy drink that has earned viral popularity among children is facing scrutiny from lawmakers and health experts over its potentially dangerous levels of caffeine

The Independent UK · Jul 9, 2023

The FDA is being asked to look into Logan Paul's energy drink, which has the caffeine of 6 Coke cans

An influencer-backed energy drink that has earned viral popularity among children is facing scrutiny from lawmakers and health experts over its potentially dangerous levels of caffeine

The Independent UK · Jul 9, 2023

Up First Briefing: Alzheimer's drug; Ukraine cluster bombs; tap water chemicals

The FDA approved the first drug shown to slow down Alzheimer's. The Biden administration will send controversial cluster bombs to Ukraine. A study estimates PFAS is in nearly half of U.S. tap water.

WEKU · Jul 7, 2023

Miracle new Alzheimer's drug which slows cognitive decline of disease to be rolled out

The Food and Drug Administration (FDA) has approved the much awaited drug Leqembi which has been shown to slow the cognitive decline caused by Alzheimer’s, the most common type of dementia

Daily Mirror · Jul 7, 2023

FDA fully approves new Alzheimer’s drug to slow down disease progression

‘Today’s action is first verification that a drug targeting underlying disease process has shown clinical benefit’

The Independent UK · Jul 7, 2023

FDA approves new Alzheimer's drug

Leqembi has proven to slow the progression of the disease, while others only target its symptoms

Salon · Jul 6, 2023

US government approves Alzheimer’s drug to slow cognitive decline

Some insurances, including the government-run Medicare, refused to pay for the drug until it received full approval.

Al Jazeera · Jul 6, 2023

Eisai Alzheimer's drug gets full US approval, widening access to the therapy

Eisai Co.’s Alzheimer’s drug Leqembi gained full approval from U.S. regulators Thursday, a move expected to widen access to the first drug cleared based on its ability to slow progression of the mind-robbing disease.

Tribune News Service · Jul 6, 2023

FDA approves Leqembi, first drug to slow Alzheimer’s progression

Eisai and Biogen's Leqembi is the first drug to slow Alzheimer's progression to receive full FDA approval.

Axios · Jul 6, 2023